MAP2K7 and neoplasm: Importantly, the MET inhibitor crizotinib effectively suppressed the RAS-MEK-ERK and AKT signaling pathways, restoring sensitivity to AMG 510 and achieving tumor regression in AMG 510-resistant xenograft models, underscoring the therapeutic potential of combining these agents (101).